85 filings
Page 4 of 5
6-K
b31v9q4fa6o 5kx
25 Sep 17
Current report (foreign)
12:00am
6-K
ja8f9yneti
15 Sep 17
Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA
12:00am
6-K
y5nnqo hka3
8 Sep 17
Current report (foreign)
12:00am
6-K
r2p7gsa0okxa1pesunp
31 Aug 17
Motif Bio to present at upcoming investor and scientific conferences
12:00am
6-K
llx35b 6d704
9 Aug 17
Current report (foreign)
12:00am
6-K
tedhgpn aiqoads
18 Jul 17
Amendment to Amphion Innovations Consultancy Agreement
12:00am
6-K
e2waefu3 nkxa432ec
6 Jul 17
Motif Bio to Present Three Posters at Idweek 2017
12:00am
6-K
gq61rfdp
23 Jun 17
Motif Bio Announces Result of General Meeting and Total Voting Rights
12:00am
6-K
vbs1exhx5q615w6f2k36
22 Jun 17
Motif Bio Invited to Present at Infectious Diseases Conference
12:00am
6-K
zjhhoq5sq1mjp
16 Jun 17
Results of Annual General Meeting
12:00am
6-K
98to pjtn
14 Jun 17
Motif Bio to Present at BIO International Convention
12:00am
6-K
ix0yoadntf3
9 Jun 17
Notification of change in holding of significant shareholder
12:00am
6-K
f3v4ki24x816rfb
6 Jun 17
Current report (foreign)
12:00am
6-K
r6dw9at4yw
2 Jun 17
Current report (foreign)
12:00am
6-K
2twe6nkmfn pvr
18 May 17
Publication of UK Annual Report and Accounts & Notice of AGM
12:00am
6-K
l3gn05qf
10 May 17
Motif Bio Appoints Scientific Opinion Leaders to Advisory Board
12:00am
6-K
dekpt
5 May 17
Motif Bio Appoints Dr. Craig Albanese as Non-Executive Director
12:00am
6-K
d50mmcczy nnu
1 May 17
Motif Bio Reports Year-End 2016 Financial Results
12:00am
6-K
48e1fp2o
18 Apr 17
Motif Bio Announces Positive Results for Iclaprim, in the REVIVE-1 Phase 3 Study
12:00am
6-K
166nyoa1ak5wsye1jb0
12 Apr 17
An acquisition or disposal of voting rights
12:00am